SEARCH:   Advanced

Blood, 15 October 2004, Vol. 104, No. 8, pp. 2600-2602. Prepublished online as a Blood First Edition Paper on June 17, 2004; DOI 10.1182/blood-2003-12-4321. This Article Full Text (PDF) All Versions of this Article: 2003-12-4321v1 104/8/2600    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ritgen, M. Articles by Dreger, P. Search for Related Content PubMed PubMed Citation Articles by Ritgen, M. Articles by Dreger, P. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 22, 2003 Accepted April 12, 2004 Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implications of minimal residual disease measurement with quantitative PCR Matthias Ritgen*, Stephan Stilgenbauer, Nils von Neuhoff, Andreas Humpe, Monika Bruggemann, Christiane Pott, Thorsten Raff, Alexander Krober, Donald Bunjes, Richard Schlenk, Norbert Schmitz, Hartmut Dohner, Michael Kneba, and Peter Dreger 2nd Dept. of Internal Medicine, University of Kiel, Kiel, Germany 3rd Dept. of Internal Medicine, University of Ulm, Ulm, Germany Inst. of Cellular and Molecular Pathology, University of Hannover, Hannover, Germany Dept. of Hematology, AK St. Georg, Hamburg, Germany * Corresponding author; email: m.ritgen{at}med2.uni-kiel.de. The aim of this study was to investigate if graft-versus-leukemia activity (GVL) conferred by allogeneic stem cell transplantation (allo-SCT) is effective in chronic lymphocytic leukemia (CLL) with unmutated VH gene status. The kinetics of residual disease (MRD) were measured by quantitative allele-specific IgH PCR in 9 patients after nonmyeloablative allo-SCT for unmutated CLL. Despite an only modest decrease in the early post-transplant phase, MRD became undetectable in 7 of 9 patients (78%) from day +100 onwards subsequent to chronic graft-versus-host disease or donor lymphocyte infusions. With a median follow-up of 25 (14-37) months, these 7 patients remain in continuous clinical and molecular remission. In contrast, PCR negativity was achieved in only 6 of 26 control patients (23%) after autologous SCT for unmutated CLL and was not durable. Taken together, this study shows for the first time that GVL-mediated immunotherapy might be effective in CLL with unmutated VH. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: CLL: to mend it or be rid of it Terry Hamblin Blood 2004 104: 2210. [Full Text] [PDF] This article has been cited by other articles: S. Stilgenbauer, T. Zenz, D. Winkler, A. Buhler, R. F. Schlenk, S. Groner, R. Busch, M. Hensel, U. Duhrsen, J. Finke, et al. Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group J. Clin. Oncol., August 20, 2009; 27(24): 3994 - 4001. [Abstract] [Full Text] [PDF] T. Nishida, M. Hudecek, A. Kostic, M. Bleakley, E. H. Warren, D. Maloney, R. Storb, and S. R. Riddell Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia Clin. Cancer Res., July 15, 2009; 15(14): 4759 - 4768. [Abstract] [Full Text] [PDF] L. Farina, C. Carniti, A. Dodero, A. Vendramin, A. Raganato, F. Spina, F. Patriarca, F. Narni, F. Benedetti, A. Olivieri, et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation Haematologica, May 1, 2009; 94(5): 654 - 662. [Abstract] [Full Text] [PDF] H.-J. Kolb Graft-versus-leukemia effects of transplantation and donor lymphocytes Blood, December 1, 2008; 112(12): 4371 - 4383. [Abstract] [Full Text] [PDF] J. Schetelig, A. van Biezen, R. Brand, D. Caballero, R. Martino, M. Itala, J. A. Garcia-Marco, L. Volin, N. Schmitz, R. Schwerdtfeger, et al. Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis J. Clin. Oncol., November 1, 2008; 26(31): 5094 - 5100. [Abstract] [Full Text] [PDF] M. L. Sorror, B. E. Storer, B. M. Sandmaier, M. Maris, J. Shizuru, R. Maziarz, E. Agura, T. R. Chauncey, M. A. Pulsipher, P. A. McSweeney, et al. Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning J. Clin. Oncol., October 20, 2008; 26(30): 4912 - 4920. [Abstract] [Full Text] [PDF] B. Friedrichs, S. Siegel, M. Kloess, A. Barsoum, J. Coggin Jr., J. Rohrer, I. Jakob, M. Tiemann, K. Heidorn, C. Schulte, et al. Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia J. Immunol., May 1, 2008; 180(9): 6374 - 6384. [Abstract] [Full Text] [PDF] A. W. Hauswirth and U. Jager Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia Haematologica, January 1, 2008; 93(1): 14 - 19. [Full Text] [PDF] A. P. Kater, M. H. J. van Oers, and T. J. Kipps Cellular immune therapy for chronic lymphocytic leukemia Blood, October 15, 2007; 110(8): 2811 - 2818. [Abstract] [Full Text] [PDF] N. Kroger, A. Badbaran, E. Holler, J. Hahn, G. Kobbe, M. Bornhauser, A. Reiter, T. Zabelina, A. R. Zander, and B. Fehse Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis Blood, February 1, 2007; 109(3): 1316 - 1321. [Abstract] [Full Text] [PDF] T. Zenz, M. Ritgen, P. Dreger, A. Krober, T. F. Barth, R. Schlenk, S. Bottcher, M. J. Hallek, M. Kneba, D. Bunjes, et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia Blood, September 15, 2006; 108(6): 2127 - 2130. [Abstract] [Full Text] [PDF] K. W. L. Yee and S. M. O'Brien Chronic Lymphocytic Leukemia: Diagnosis and Treatment Mayo Clin. Proc., August 1, 2006; 81(8): 1105 - 1129. [Abstract] [Full Text] [PDF] C. Moreno, N. Villamor, D. Colomer, J. Esteve, E. Gine, A. Muntanola, E. Campo, F. Bosch, and E. Montserrat Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia Blood, June 1, 2006; 107(11): 4563 - 4569. [Abstract] [Full Text] [PDF] C. Pott, C. Schrader, S. Gesk, L. Harder, M. Tiemann, T. Raff, M. Bruggemann, M. Ritgen, B. Gahn, M. Unterhalt, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma Blood, March 15, 2006; 107(6): 2271 - 2278. [Abstract] [Full Text] [PDF] E. Montserrat, C. Moreno, J. Esteve, A. Urbano-Ispizua, E. Gine, and F. Bosch How I treat refractory CLL Blood, February 15, 2006; 107(4): 1276 - 1283. [Abstract] [Full Text] [PDF] B. L. Abbott Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment Oncologist, January 1, 2006; 11(1): 21 - 30. [Abstract] [Full Text] [PDF] J. G. Gribben, D. Zahrieh, K. Stephans, L. Bartlett-Pandite, E. P. Alyea, D. C. Fisher, A. S. Freedman, P. Mauch, R. Schlossman, L. V. Sequist, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia Blood, December 15, 2005; 106(13): 4389 - 4396. [Abstract] [Full Text] [PDF] C. Moreno and E. Montserrat In Reply: J. Clin. Oncol., November 1, 2005; 23(31): 8127 - 8128. [Full Text] [PDF] D. Caballero, J. A. Garcia-Marco, R. Martino, V. Mateos, J. M. Ribera, J. Sarra, A. Leon, G. Sanz, J. de la Serna, R. Cabrera, et al. Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-) Clin. Cancer Res., November 1, 2005; 11(21): 7757 - 7763. [Abstract] [Full Text] [PDF] S. Z. Pavletic, I. F. Khouri, M. Haagenson, R. J. King, P. J. Bierman, M. R. Bishop, M. Carston, S. Giralt, A. Molina, E. A. Copelan, et al. Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research J. Clin. Oncol., August 20, 2005; 23(24): 5788 - 5794. [Abstract] [Full Text] [PDF] M. L. Sorror, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. J. Stuart, U. Hegenbart, E. Agura, T. R. Chauncey, J. Leis, M. Pulsipher, et al. Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia J. Clin. Oncol., June 1, 2005; 23(16): 3819 - 3829. [Abstract] [Full Text] [PDF] C. Moreno, N. Villamor, D. Colomer, J. Esteve, R. Martino, J. Nomdedeu, F. Bosch, A. Lopez-Guillermo, E. Campo, J. Sierra, et al. Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated VH Gene in Patients With Chronic Lymphocytic Leukemia J. Clin. Oncol., May 20, 2005; 23(15): 3433 - 3438. [Abstract] [Full Text] [PDF] J. G. Gribben Salvage Therapy for CLL and the Role of Stem Cell Transplantation Hematology, January 1, 2005; 2005(1): 292 - 298. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020